Virtu Financial LLC acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 13,883 shares of the biopharmaceutical company’s stock, valued at approximately $94,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new position in ProQR Therapeutics during the second quarter worth $43,000. Captrust Financial Advisors purchased a new position in ProQR Therapeutics during the first quarter worth $50,000. HighPoint Advisor Group LLC purchased a new position in ProQR Therapeutics during the second quarter worth $67,000. Lindbrook Capital LLC boosted its stake in ProQR Therapeutics by 31.3% during the second quarter. Lindbrook Capital LLC now owns 12,600 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 3,000 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in ProQR Therapeutics during the first quarter worth $101,000. 83.99% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of ProQR Therapeutics in a research note on Monday, October 18th. Zacks Investment Research lowered shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 12th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of ProQR Therapeutics in a research note on Thursday, September 9th. Chardan Capital reissued a “buy” rating and set a $18.00 target price on shares of ProQR Therapeutics in a research note on Friday, September 10th. Finally, Evercore ISI reaffirmed a “buy” rating and issued a $17.00 price objective on shares of ProQR Therapeutics in a research note on Sunday, November 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $26.17.
ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.00% and a negative net margin of 3,747.12%. On average, equities analysts predict that ProQR Therapeutics will post -1.02 earnings per share for the current fiscal year.
ProQR Therapeutics Company Profile
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a.
Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics (NASDAQ:PRQR).
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.